This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention

This study has been completed.
Information provided by:
Onassis Cardiac Surgery Centre Identifier:
First received: June 27, 2006
Last updated: August 22, 2007
Last verified: August 2007
The prevention of contrast-mediated nephropathy (CMN), which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast induced renal vasoconstriction is believed to play a pivotal role in the CMN mechanism. The aim of this study is to examine the efficacy of the prostacyclin analogue iloprost (dose 1ng/kg/min) in preventing CMN in high-risk patients undergoing a coronary procedure.

Condition Intervention Phase
Renal Insufficiency, Chronic Coronary Angiography Angioplasty, Transluminal, Percutaneous Coronary Drug: Iloprost Drug: Placebo Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients With Preexisting Renal Dysfunction Undergoing a Coronary Procedure

Resource links provided by NLM:

Further study details as provided by Onassis Cardiac Surgery Centre:

Primary Outcome Measures:
  • CMN is defined as an absolute increase of serum creatinine concentration of at least 0.5 mg/dl [ Time Frame: 2-5 days after the procedure ]
  • or CMN is defined as a relative rise of at least 25% from baseline on the follow-up [ Time Frame: blood sample drawn at 2-5 days after the procedure ]

Secondary Outcome Measures:
  • Differences in the progression of serum creatinine concentrations and creatinine clearance among the study groups [ Time Frame: 2-5 days after the procedure ]

Enrollment: 208
Study Start Date: November 2005
Study Completion Date: July 2007
Arms Assigned Interventions
Experimental: 1
Drug: Iloprost
Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
Placebo Comparator: 2
Drug: Placebo
Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients undergoing clinically driven, non-emergent coronary angiography or intervention in our institution were eligible for inclusion if their serum creatinine concentration was ≥1.4 mg/dl (124 μmol/l) and/or their creatinine clearance was <60 ml/min on their most recent sample drawn within 1 month of the planned procedure

Exclusion Criteria:

  • Circulatory shock for any reason, systolic blood pressure <95 mm Hg
  • Known acute renal failure
  • End-stage renal disease requiring dialysis
  • Intravascular administration of a contrast medium within the previous 10 days
  • Anticipated re-administration of contrast medium within the following 6 days
  • Inability to administer intravenous hydration at least 4 h before the procedure or study medication at least 30 min before the procedure
  • Primary intervention for acute infarction with ST elevation
  • A procedure performed within 2 h of acute hospital admission
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00345501

Onassis Cardiac Surgery Centre
Athens, Greece, 17674
Sponsors and Collaborators
Onassis Cardiac Surgery Centre
Principal Investigator: Konstantinos Spargias, MD Onassis Cardiac Surgery Centre
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00345501     History of Changes
Other Study ID Numbers: OCS IEC 265
EudraCT 2005-001887-30
Study First Received: June 27, 2006
Last Updated: August 22, 2007

Keywords provided by Onassis Cardiac Surgery Centre:
contrast media
contrast nephropathy

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency
Renal Insufficiency, Chronic
Urologic Diseases
Platelet Aggregation Inhibitors
Vasodilator Agents processed this record on September 19, 2017